Physician profile
Nathan E Riddell
NPI 1245670983
$6,655.28
in general payments reported to CMS, 2019-2025
25 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.77 · 2020: $80.30 · 2021: $129 · 2022: $1,402 · 2023: $2,954 · 2024: $1,562 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,750 · Food and Beverage: $1,430 · Travel and Lodging: $764.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,750.00 |
| Food and Beverage | $1,429.51 |
| Travel and Lodging | $764.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,750.00 | 2023 | Impella |
| Penumbra, INC. | $1,016.61 | 2022-2024 | Indigo System |
| Medtronic, INC. | $1,015.84 | 2022 | |
| Boston Scientific Corporation | $405.94 | 2023-2025 | Wolverine Coronary Cutting Balloon, Eluvia, Opticross 6 |
| Amgen INC. | $209.32 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $199.75 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $134.19 | 2022-2025 | Verquvo, Bridion |
| Pfizer INC. | $121.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.15 | 2021-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $115.13 | 2021-2024 | Xarelto |
| Abbott Laboratories | $99.77 | 2019 | |
| Alnylam Pharmaceuticals INC. | $67.77 | 2025 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $66.58 | 2022-2024 | Camzyos |
| Bard Peripheral Vascular, INC. | $62.77 | 2025 | Rotarexs 6 F X 135 Cm |
| Lantheus Medical Imaging, INC. | $48.30 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $36.53 | 2020-2022 | |
| Esperion Therapeutics, INC. | $29.26 | 2020 | |
| Cardiva Medical, INC. | $28.38 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Shockwave Medical, INC | $28.21 | 2022 | |
| Bridgebio Pharma, INC. | $22.81 | 2025 | Attruby |
| Opsens INC. | $22.60 | 2022 | |
| Veryan Medical Incorporated | $21.00 | 2025 | Biomimics 3d Vascular Stent System |
| Chiesi USA, INC. | $15.26 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.26 | 2023 | |
| Altathera Pharmaceuticals LLC | $8.80 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Riddell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.